Background: Reports regarding long-term follow-up including quality-of-life assessment, pulmonary function, and donor-site morbidity after operative treatment for sternal osteomyelitis are rare.
Methods: Data for 69 consecutive patients were acquired from patients' charts and contact with patients and general practitioners, with special reference to treatment and clinical course. Twenty-four patients were interviewed and physically examined (mean follow-up, 4 years; range, 1 to 9 years). Fifteen of the patients underwent pulmonary function tests, cine magnetic resonance imaging, and pectoralis strength testing using a dynamometer to record butterfly arm compressive movements. Statistical analysis was performed to identify factors influencing wound healing and survival.
Results: Mortality rates were 10.1 percent at 30 days, 18.5 percent at 1 year, and 27.0 percent at 5 years (n = 69). In 36.2 percent of the patients, wound-healing difficulties requiring reoperation occurred. Independent of the extent of sternal resection, dynamic pulmonary function values were decreased compared with normal values (n = 15). Dynamometer assessment revealed decreases of 1.5 percent in dynamic maximum strength, 9.7 percent in maximum isometric strength, and 47.2 percent in strength endurance compared with the healthy age-matched control group. Magnetic resonance imaging showed no sign of recurrent osteomyelitis (n = 15). Muscle function was preserved in 93 percent of the patients. Eighty-three percent of the interviewed patients considered their general condition better and 17 percent considered it worse than before the treatment (n = 24).
Conclusions: Pectoralis muscle transfer represents a safe and simple procedure. Although strength loss and pain are considerable, quality of life is improved significantly. Pulmonary function impairment is most likely not exclusively attributable to the muscle transfer or the sternum resection.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/PRS.0b013e318199f49f | DOI Listing |
TIGIT and PVRIG are immune checkpoints co-expressed on activated T and NK cells, contributing to tumor immune evasion. Simultaneous blockade of these pathways may enhance therapeutic efficacy, positioning them as promising dual targets for cancer immunotherapy. This study aimed to develop a bispecific antibody (BsAb) to co-target TIGIT and PVRIG.
View Article and Find Full Text PDFCirc Genom Precis Med
January 2025
Centre for Heart Lung Innovation, University of British Columbia, Vancouver. (K.H., M.A., L.R., Y.L., A.S., H.H., L.R.B., Z.W.L.).
Background: Protein-truncating mutations in the titin gene are associated with increased risk of atrial fibrillation. However, little is known about the underlying pathophysiology.
Methods: We identified a heterozygous titin truncating variant (TTNtv) in a patient with unexplained early onset atrial fibrillation and normal ventricular function.
N Am Spine Soc J
December 2024
Department of Orthopaedic Surgery, SSM Health Saint Louis University Hospital, Saint Louis, MO 63110, United States.
Background: Pediatric spinal deformity surgery affects ultimate spinal height in the growing child. This effect on ultimate spinal height has also been shown to affect pulmonary development and ultimately pulmonary function. There has been an increasing trend toward growth-friendly spinal surgery in early onset scoliosis to minimize the negative consequences of early spinal fusion surgery.
View Article and Find Full Text PDFFront Immunol
January 2025
Immunology Research Center, National Health Research Institute, Zhunan, Taiwan.
CASK, a MAGUK family scaffold protein, regulates gene expression as a transcription co-activator in neurons. However, the mechanism of CASK nucleus translocation and the regulatory function of CASK in myeloid cells remains unclear. Here, we investigated its role in H5N1-infected macrophages.
View Article and Find Full Text PDFFront Immunol
January 2025
Faculty of Life and Biotechnology, Kunming University of Science and Technology, Kunming, China.
Background: Dysbiosis of the lung microbiome can contribute to the initiation and progression of lung cancer. Synchronous multiple primary lung cancer (sMPLC) is an increasingly recognized subtype of lung cancer characterized by high morbidity, difficulties in early detection, poor prognosis, and substantial clinical challenges. However, the relationship between sMPLC pathogenesis and changes in the lung microbiome remains unclear.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!